Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/176879
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer’s Disease: Potential and Limitations

AutorCosín-Tomás, Marta CSIC ORCID; Antonell, Anna; Lladó, Albert; Alcolea, Daniel; Fortea, Juan; Ezquerra, Mario; Lleó, Alberto; Martí, María-José; Pallàs, Mercè; Sánchez-Valle, Raquel; Molinuevo, José Luis; Sanfeliu, Coral CSIC ORCID; Kaliman, Perla CSIC
Palabras clavemiRNA
Alzheimer’s disease
Plasma biomarker
Preclinical
miR-34a-5p
miR-545-3p
Fecha de publicaciónsep-2017
EditorSpringer Nature
CitaciónMolecular Neurobiology 54(7): 5550-5562 (2017)
ResumenPlasma microRNAs (miRNAs) have been proposed as potential biomarkers in Alzheimer’s disease (AD). Here, we explored their use as early sensors of the preclinical phase of the disease, when brain pathology is being developed and no cognitive loss is detected. For this purpose, we analyzed a set of ten mature plasma miRNAs in symptomatic patients with AD from a cohort that also included healthy controls (HC) and patients with preclinical Alzheimer’s disease (PAD) (cohort 1). Plasmas from subjects with Parkinson’s disease (PD) were used to control for disease specificity. We found that miR-15b-5p, miR-34a-5p, miR-142-3p, and miR-545-3p levels significantly distinguished AD from PD and HC subjects. We next examined the expression of these four miRNAs in plasma from subjects with PAD. Among these, miR-34a-5p and miR-545-3p presented good diagnostic accuracy to distinguish both AD and PAD from HC subjects, according to the receiver operating characteristic (ROC) curve analysis. Both miRNAs also demonstrated a significant positive correlation with Aβ1–42 levels in cerebrospinal fluid (CSF). Taking into account the clinical potential of these findings, we decided to validate the diagnostic accuracy of miR-34a-5p and miR-545-3p in plasma samples from an independent cohort (cohort 2), in which we did not observe the alterations described by us and others in AD and PAD samples. Although miR-34a-5p and miR-545-3p might be promising early biomarker candidates for AD, our study highlights possible sources of variability in miRNA analysis across hospitals, which currently prevents their use as reliable clinical tools.
Versión del editorhttps://doi.org/10.1007/s12035-016-0088-8
URIhttp://hdl.handle.net/10261/176879
DOI10.1007/s12035-016-0088-8
ISSN0893-7648
E-ISSN1559-1182
Aparece en las colecciones: (IIBB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

107
checked on 13-mar-2024

WEB OF SCIENCETM
Citations

101
checked on 23-feb-2024

Page view(s)

241
checked on 18-mar-2024

Download(s)

36
checked on 18-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.